{"id":"NCT00293267","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (MK0518-018 EXT2)","officialTitle":"A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 in Combination With an Optimized Background Therapy (OBT), Versus Optimized Background Therapy Alone, in HIV-Infected Patients With Documented Resistance to at Least 1 Drug in Each of the 3 Classes of Licensed Oral Antiviral Therapies","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-02","primaryCompletion":"2007-08","completion":"2011-05","firstPosted":"2006-02-17","resultsPosted":"2009-09-28","lastUpdate":"2015-09-07"},"enrollment":352,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["HIV Infections"],"interventions":[{"type":"DRUG","name":"raltegravir potassium","otherNames":["ISENTRESSâ„¢"]},{"type":"DRUG","name":"Comparator: Placebo","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"PLACEBO_COMPARATOR"}],"summary":"This study will investigate the safety and efficacy of raltegravir as a therapy for HIV-infected patients failing current therapy with 3-class antiviral resistance.","primaryOutcome":{"measure":"Percentage of Participants Achieving HIV RNA <400 Copies/mL at Week 16","timeFrame":"16 Weeks","effectByArm":[{"arm":"Raltegravir 400 mg b.i.d. + OBT","deltaMin":77.7,"sd":null},{"arm":"Placebo + OBT","deltaMin":41,"sd":null}],"pValues":[]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["18650512","18650513","20085491"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":97,"n":232},"commonTop":["Diarrhoea","Nasopharyngitis","Bronchitis","Headache","Nausea"]}}